General biomarker recommendations for lymphoma

Lisa Rimsza, Yuri Fedoriw, Louis M. Staudt, Ari Melnick, Randy Gascoyne, Michael Crump, Lawrence Baizer, Kai Fu, Eric Hsi, John W C Chan, Lisa McShane, John P. Leonard, Brad S. Kahl, Richard F. Little, Jonathan W. Friedberg, Lale Kostakoglu

Research output: Contribution to journalReview article

Abstract

Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of these tumors are indolent. The ability to determine treatment needs at diagnosis remains problematic for some of the tumors, such as in follicular lymphomas. Major clinical advances will likely depend on precision oncology that will enable identification of specific disease entities, prognostic determination at diagnosis, and identification of precise therapeutic targets and essential pathways. However, refinement in diagnostic evaluation is an evolving science. The ability to determine prognosis at diagnosis is variable, and for many of the lymphoid malignancies prognosis can only be made after initial treatment. Clinical trials that aim to evaluate specific features of these diseases are required in order to advance clinical practice that meaningfully addresses this important public health challenge. Herein, we describe the process and general recommendation from the National Cancer Institute (NCI) clinical trials planning meeting in November 2014 to address clinical trial design and biomarker proposals in the context of NCI-supported lymphoma clinical trials in the National Clinical Trials Network.

Original languageEnglish (US)
Article numberdjw250
JournalJournal of the National Cancer Institute
Volume108
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Lymphoma
Biomarkers
Clinical Trials
National Cancer Institute (U.S.)
Neoplasms
Follicular Lymphoma
Public Health
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rimsza, L., Fedoriw, Y., Staudt, L. M., Melnick, A., Gascoyne, R., Crump, M., ... Kostakoglu, L. (2016). General biomarker recommendations for lymphoma. Journal of the National Cancer Institute, 108(12), [djw250]. https://doi.org/10.1093/jnci/djw250

General biomarker recommendations for lymphoma. / Rimsza, Lisa; Fedoriw, Yuri; Staudt, Louis M.; Melnick, Ari; Gascoyne, Randy; Crump, Michael; Baizer, Lawrence; Fu, Kai; Hsi, Eric; Chan, John W C; McShane, Lisa; Leonard, John P.; Kahl, Brad S.; Little, Richard F.; Friedberg, Jonathan W.; Kostakoglu, Lale.

In: Journal of the National Cancer Institute, Vol. 108, No. 12, djw250, 01.12.2016.

Research output: Contribution to journalReview article

Rimsza, L, Fedoriw, Y, Staudt, LM, Melnick, A, Gascoyne, R, Crump, M, Baizer, L, Fu, K, Hsi, E, Chan, JWC, McShane, L, Leonard, JP, Kahl, BS, Little, RF, Friedberg, JW & Kostakoglu, L 2016, 'General biomarker recommendations for lymphoma', Journal of the National Cancer Institute, vol. 108, no. 12, djw250. https://doi.org/10.1093/jnci/djw250
Rimsza L, Fedoriw Y, Staudt LM, Melnick A, Gascoyne R, Crump M et al. General biomarker recommendations for lymphoma. Journal of the National Cancer Institute. 2016 Dec 1;108(12). djw250. https://doi.org/10.1093/jnci/djw250
Rimsza, Lisa ; Fedoriw, Yuri ; Staudt, Louis M. ; Melnick, Ari ; Gascoyne, Randy ; Crump, Michael ; Baizer, Lawrence ; Fu, Kai ; Hsi, Eric ; Chan, John W C ; McShane, Lisa ; Leonard, John P. ; Kahl, Brad S. ; Little, Richard F. ; Friedberg, Jonathan W. ; Kostakoglu, Lale. / General biomarker recommendations for lymphoma. In: Journal of the National Cancer Institute. 2016 ; Vol. 108, No. 12.
@article{ef52efeed9ba49729ac4a300b1093119,
title = "General biomarker recommendations for lymphoma",
abstract = "Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of these tumors are indolent. The ability to determine treatment needs at diagnosis remains problematic for some of the tumors, such as in follicular lymphomas. Major clinical advances will likely depend on precision oncology that will enable identification of specific disease entities, prognostic determination at diagnosis, and identification of precise therapeutic targets and essential pathways. However, refinement in diagnostic evaluation is an evolving science. The ability to determine prognosis at diagnosis is variable, and for many of the lymphoid malignancies prognosis can only be made after initial treatment. Clinical trials that aim to evaluate specific features of these diseases are required in order to advance clinical practice that meaningfully addresses this important public health challenge. Herein, we describe the process and general recommendation from the National Cancer Institute (NCI) clinical trials planning meeting in November 2014 to address clinical trial design and biomarker proposals in the context of NCI-supported lymphoma clinical trials in the National Clinical Trials Network.",
author = "Lisa Rimsza and Yuri Fedoriw and Staudt, {Louis M.} and Ari Melnick and Randy Gascoyne and Michael Crump and Lawrence Baizer and Kai Fu and Eric Hsi and Chan, {John W C} and Lisa McShane and Leonard, {John P.} and Kahl, {Brad S.} and Little, {Richard F.} and Friedberg, {Jonathan W.} and Lale Kostakoglu",
year = "2016",
month = "12",
day = "1",
doi = "10.1093/jnci/djw250",
language = "English (US)",
volume = "108",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - General biomarker recommendations for lymphoma

AU - Rimsza, Lisa

AU - Fedoriw, Yuri

AU - Staudt, Louis M.

AU - Melnick, Ari

AU - Gascoyne, Randy

AU - Crump, Michael

AU - Baizer, Lawrence

AU - Fu, Kai

AU - Hsi, Eric

AU - Chan, John W C

AU - McShane, Lisa

AU - Leonard, John P.

AU - Kahl, Brad S.

AU - Little, Richard F.

AU - Friedberg, Jonathan W.

AU - Kostakoglu, Lale

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of these tumors are indolent. The ability to determine treatment needs at diagnosis remains problematic for some of the tumors, such as in follicular lymphomas. Major clinical advances will likely depend on precision oncology that will enable identification of specific disease entities, prognostic determination at diagnosis, and identification of precise therapeutic targets and essential pathways. However, refinement in diagnostic evaluation is an evolving science. The ability to determine prognosis at diagnosis is variable, and for many of the lymphoid malignancies prognosis can only be made after initial treatment. Clinical trials that aim to evaluate specific features of these diseases are required in order to advance clinical practice that meaningfully addresses this important public health challenge. Herein, we describe the process and general recommendation from the National Cancer Institute (NCI) clinical trials planning meeting in November 2014 to address clinical trial design and biomarker proposals in the context of NCI-supported lymphoma clinical trials in the National Clinical Trials Network.

AB - Lymphoid malignancies are a heterogeneous group of tumors that have distinctive clinical and biological behaviors. The increasing prevalence of disease reflects both treatment advances and the fact that some of these tumors are indolent. The ability to determine treatment needs at diagnosis remains problematic for some of the tumors, such as in follicular lymphomas. Major clinical advances will likely depend on precision oncology that will enable identification of specific disease entities, prognostic determination at diagnosis, and identification of precise therapeutic targets and essential pathways. However, refinement in diagnostic evaluation is an evolving science. The ability to determine prognosis at diagnosis is variable, and for many of the lymphoid malignancies prognosis can only be made after initial treatment. Clinical trials that aim to evaluate specific features of these diseases are required in order to advance clinical practice that meaningfully addresses this important public health challenge. Herein, we describe the process and general recommendation from the National Cancer Institute (NCI) clinical trials planning meeting in November 2014 to address clinical trial design and biomarker proposals in the context of NCI-supported lymphoma clinical trials in the National Clinical Trials Network.

UR - http://www.scopus.com/inward/record.url?scp=85016081670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016081670&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw250

DO - 10.1093/jnci/djw250

M3 - Review article

C2 - 27986882

AN - SCOPUS:85016081670

VL - 108

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

M1 - djw250

ER -